. Author manuscript; available in PMC: 2021 Nov 28.

Published in final edited form as: Leukemia. 2021 May 28;35(10):2906–2916. doi: 10.1038/s41375-021-01284-4

Table 1.

Excess relative risk (ERR) per Gy (and 95% CI) of lymphoma and multiple myeloma obtained from fitting semi-parametric linear (in dose) excess relative risk models in relation to active bone marrow dose.^a

Endpoint	Cases	ERR/Gy (95% CI)	p-value^b	Inter-cohort heterogeneity p-value
All lymphoma	593	−0.001 (−0.255^c, 0.279)	>0.999	0.197
Non-Hodgkin lymphoma (NHL) + chronic lymphocytic leukaemia (CLL)	488	0.099 (−0.149, 0.433)	0.480	0.344
Non-Hodgkin lymphoma (NHL)	422	0.068 (−0.253^c, 0.421)	0.650	0.606
Chronic lymphocytic leukaemia (CLL)	66	0.320 (−0.678^c, 1.712)	0.445	0.912
Hodgkin lymphoma (HL)	107	−0.113 (−0.669^c, 0.709)	0.737	0.995
Multiple myeloma (MM)	122	0.149 (−0.513^c, 1.063)	0.654	0.985

Models are as described by Appendix B (B2), stratifying by cohort, sex, age and year of follow-up (using intervals of age and year of follow-up defined by person-year table, as in Appendix A Table A1). Unless otherwise stated, all confidence intervals are based on the profile likelihood.

p-value of improvement in fit over null model (without dose trend).

Wald-based confidence limit.